Created at	Source	Raw Value	Validated value
Oct. 26, 2020, 11:31 p.m.	usa	To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA);Improvement in ARDS associated clinical symptoms cause;F2-Isoprostane;Total leucocyte count;Hb;IgG;Serum c-reactive protein (CRP);IL-6 reduction	To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA);Improvement in ARDS associated clinical symptoms cause;F2-Isoprostane;Total leucocyte count;Hb;IgG;Serum c-reactive protein (CRP);IL-6 reduction